FGFR3 overexpression enhances the cisplatin resistance in ovarian cancer through elevating the phosphorylation of the epidermal growth factor receptor (EGFR) and further activating the PI3K/AKT signaling pathway [102]. Here, FGFR3 is linked to ovarian carcinoma.